WordNet

to remain unmolested, undisturbed, or uninterrupted -- used only in infinitive form; "let her be"
work in a specific place, with a specific subject, or in a specific function; "He is a herpetologist"; "She is our resident philosopher" (同)follow
have life, be alive; "Our great leader is no more"; "My grandfather lived until the end of war" (同)live
be identical to; be someone or something; "The president of the company is John Smith"; "This is my house"
happen, occur, take place; "I lost my wallet; this was during the visit to my parents house"; "There were two hundred people at his funeral"; "There was a lot of noise in the kitchen"
have the quality of being; (copula, used with an adjective or a predicate noun); "John is rich"; "This is not a good answer"
occupy a certain position or area; be somewhere; "Where is my umbrella?" "The toolshed is in the back"; "What is behind this behavior?"
spend or use time; "I may be an hour"
stake on the outcome of an issue; "I bet $100 on that new horse"; "She played all her money on the dark horse" (同)wager, play
the act of gambling; "he did it on a bet" (同)wager
maintain with or as if with a bet; "I bet she will be there!" (同)wager
second in order of importance; "the candidate, considered a beta male, was perceived to be unable to lead his party to victory"
the 2nd letter of the Greek alphabet
preliminary or testing stage of a software or hardware product; "a beta version"; "beta software"
a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
drug that has the effects of epinephrine (同)adrenergic_drug
relating to epinephrine (its release or action) (同)sympathomimetic

PrepTutorEJDIC

《連結語として補語を伴なって…『である』,…だ,…です / 《位置・場所を表す語句を伴って》(…に)『ある』,いる(occupy a place or situation) / 〈物事が〉『存在する』,ある(exist);〈生物が〉生存する,生きている(live) / 行われる,起こる,発生する(take place, occur) / 存続する,そのままでいる(remain as before) / 《『be to』 do》 / …する予定である,…することになっている / …すべきだ / 《受動態の不定詞を伴って》…できる / 《命令》…するのだ / 《条件節に》…する意図がある / 《『if…were to』 do》…するとしたなら / 《『be』 do『ing』》《進行形》 / 《進行中の動作》…している,しつつある / 《近い未来》…しようとしている,するつもり / 《動作の反復》(いつも)…している / 《『be』+『他動詞の過去分詞』》《受動態》…される,されている / 《『be』+『自動詞の過去分詞』》《完了形》…した[状態にある]
『かけ』・(…との)かけ《+『with』+『名』》 / かけた物(金) / かけの対象 / 〈金・物〉'を'『かける』 / (かけ事・ゲームなどで)〈人〉‘と'『かけをする』《+『名』〈人〉+『on』+『名』》 / (…に)『かける』《+『on』(『against』)+『名』(one's do『ing』)》
ベータ(ギリシア語アルファベットの第2文字;B,β;英語のB,b に遭当)
=sense organ / 受信装置

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/07/17 14:18:05」(JST)

wiki en

[Wiki en表示]

The beta-3 adrenergic receptor (β₃ adrenoreceptor), also known as ADRB3, is a beta-adrenergic receptor, and also denotes the human gene encoding it.^[1]

Function

Actions of the β₃ receptor include:

Enhancement of lipolysis in adipose tissue.^[2]
Thermogenesis in skeletal muscle^[3]

It is located mainly in adipose tissue and is involved in the regulation of lipolysis and thermogenesis. Some β₃ agonists have demonstrated antistress effects in animal studies, suggesting it also has a role in the central nervous system (CNS). Beta3-Receptors are found in the gallbladder, urinary bladder, and in brown adipose tissue. Their role in gallbladder physiology is unknown, but they are thought to play a role in lipolysis and thermogenesis in brown fat. In the urinary bladder it is thought to cause relaxation of the bladder and prevention of urination.^[4]

Mechanism of action

Beta adrenergic receptors are involved in the epinephrine- and norepinephrine-induced activation of adenylate cyclase through the action of the G proteins of the type G_s.^[1]

Ligands

Agonists

Amibegron (SR-58611A)^[5]^[6]
CL-316,243^[7]
L-742,791^[8]
L-796,568^[9]
LY-368,842
Mirabegron (YM-178),^[10] approved for treatment of overactive bladder in Japan, United States, UK, Canada, China and India.
Ro40-2148
Solabegron (GW-427,353)^[11]

A selective β₃ agonist has potential weight loss effects through modulation of lipolysis.^[2]

Antagonists

L-748,328^[8]
L-748,337^[8]
SR 59230A was thought to be a selective β₃ antagonist^[12] but later found to also be an antagonist of the α₁ receptor.^[13]

Interactions

Beta-3 adrenergic receptor has been shown to interact with Src.^[14]

References

^ ^a ^b "Entrez Gene: ADRB3 adrenergic, beta-3-, receptor".
^ ^a ^b Ferrer-Lorente R, Cabot C, Fernández-López JA, Alemany M (September 2005). "Combined effects of oleoyl-estrone and a β₃-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats". Life Sciences 77 (16): 2051–8. doi:10.1016/j.lfs.2005.04.008. PMID 15935402.
^ Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4. Page 163
^ Sawa M, Harada H (2006). "Recent Developments in the Design of Orally Bioavailable β3-Adrenergic Receptor Agonists". Current Medicinal Chemistry 13 (1): 25–37. doi:10.2174/092986706775198006. PMID 16457637.
^ Consoli D, Leggio GM, Mazzola C, Micale V, Drago F (November 2007). "Behavioral effects of the β₃ adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?". European Journal of Pharmacology 573 (1–3): 139–47. doi:10.1016/j.ejphar.2007.06.048. PMID 17669397.
^ Overstreet DH, Stemmelin J, Griebel G (June 2008). "Confirmation of antidepressant potential of the selective β₃ adrenoceptor agonist amibegron in an animal model of depression". Pharmacology, Biochemistry, and Behavior 89 (4): 623–6. doi:10.1016/j.pbb.2008.02.020. PMID 18358519.
^ Fu L, Isobe K, Zeng Q, Suzukawa K, Takekoshi K, Kawakami Y (2008). "The effects of beta(3)-adrenoceptor agonist CL-316,243 on adiponectin, adiponectin receptors and tumor necrosis factor-alpha expressions in adipose tissues of obese diabetic KKAy mice". European Journal of Pharmacology 584 (1): 202–6. doi:10.1016/j.ejphar.2008.01.028. PMID 18304529.
^ ^a ^b ^c Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y et al. (Aug 1999). "Potent and selective human beta(3)-adrenergic receptor antagonists.". The Journal of Pharmacology and Experimental Therapeutics 290 (2): 649–55. PMID 10411574.
^ Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WH et al. (2002). "Effect of a 28-d treatment with L-796568, a novel β₃-adrenergic receptor agonist, on energy expenditure and body composition in obese men". The American Journal of Clinical Nutrition 76 (4): 780–8. PMID 12324291.
^ Gras J (2012). "Mirabegron for the treatment of overactive bladder". Drugs of today (Barcelona, Spain : 1998) 48 (1): 25–32. doi:10.1358/dot.2012.48.1.1738056. PMID 22384458.
^ Hicks A, McCafferty GP, Riedel E, Aiyar N, Pullen M, Evans C et al. (October 2007). "GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog". The Journal of Pharmacology and Experimental Therapeutics 323 (1): 202–9. doi:10.1124/jpet.107.125757. PMID 17626794.
^ Nisoli E, Tonello C, Landi M, Carruba MO (1996). "Functional studies of the first selective β₃-adrenergic receptor antagonist SR 59230A in rat brown adipocytes". Mol. Pharmacol. 49 (1): 7–14. PMID 8569714.
^ Bexis S, Docherty JR (April 2009). "Role of α1- and β3-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse". British Journal of Pharmacology 158 (1): 259–66. doi:10.1111/j.1476-5381.2009.00186.x. PMC 2795232. PMID 19422394.
^ Cao W, Luttrell LM, Medvedev AV, Pierce KL, Daniel KW, Dixon TM et al. (2000). "Direct binding of activated c-Src to the beta 3-adrenergic receptor is required for MAP kinase activation". J. Biol. Chem. 275 (49): 38131–4. doi:10.1074/jbc.C000592200. PMID 11013230.

External links

"β₃-adrenoceptor". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.

This transmembrane receptor-related article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 肥満の病因 pathogenesis of obesity
2. 安定狭心症のマネージメントにおけるβ遮断剤 beta blockers in the management of stable angina pectoris
3. 収縮能障害による心不全におけるβブロッカーの使用 use of beta blockers in heart failure due to systolic dysfunction
4. 肥満の薬物療法 drug therapy of obesity
5. 収縮能障害による心不全におけるβブロッカー使用の理論的根拠および臨床試験 rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction

English Journal

Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments.

Heisen M1, Baeten SA1, Verheggen BG1, Stoelzel M2, Hakimi Z2, Ridder A2, van Maanen R2, Stolk EA3.
Current medical research and opinion.Curr Med Res Opin.2016 Feb 12:1-10. [Epub ahead of print]
Objective We examined patient and treating physician (general practitioners, urologists, and [uro]gynecologists) preferences for oral pharmacotherapy (antimuscarinics and beta-3 adrenoceptor agonists) for overactive bladder to gain a deeper understanding of which attributes drive their treatment dec
PMID 26789823

Association analysis of the beta-3 adrenergic receptor Trp64Arg (rs4994) polymorphism with urate and gout.

Fatima T1, Altaf S1, Phipps-Green A1, Topless R1, Flynn TJ1, Stamp LK2, Dalbeth N3, Merriman TR4.
Rheumatology international.Rheumatol Int.2016 Feb;36(2):255-61. doi: 10.1007/s00296-015-3370-6. Epub 2015 Sep 26.
The Arg64 allele of variant rs4994 (Trp64Arg) in the β3-adrenergic receptor gene has been associated with increased serum urate and risk of gout. Our objective was to investigate the relationship of rs4994 with serum urate and gout in New Zealand European, Māori and Pacific subjects. A total of 17
PMID 26410617

Discovery of benzamides as potent human β3 adrenergic receptor agonists.

Zhu C1, Kar NF2, Li B3, Costa M2, Dingley KH3, Di Salvo J3, Ha SN3, Hurley AL2, Li X2, Miller RR3, Salituro GM2, Struthers M3, Weber AE3, Hale JJ2, Edmondson SD3.
Bioorganic & medicinal chemistry letters.Bioorg Med Chem Lett.2016 Jan 1;26(1):55-9. doi: 10.1016/j.bmcl.2015.11.030. Epub 2015 Nov 11.
The paper will describe the synthesis and SAR studies that led to the discovery of benzamide (reverse amide) as potent and selective human β3-adrenergic receptor agonist. Based on conformationally restricted pyrrolidine scaffold we discovered earlier, pyrrolidine benzoic acid intermediate 22 was sy
PMID 26590100

Japanese Journal

4) 幼少期の高アンドロゲン環境とインスリン抵抗性からみたPCOSの病因および管理に関する検討(シンポジウム3:生殖「多嚢胞性卵巣症候群(PCOS)の病因・病態と管理」,第65回日本産科婦人科学会・学術講演会)

日本産科婦人科學會雜誌 65(12), 2721-2736, 2013-12-01
NAID 110009685697

Beta-3-adrenergic receptor Trp64Arg polymorphism : does it modulate the relationship between exercise and percentage of body fat in young adult Japanese males?

Environmental health and preventive medicine 18(4), 323-329, 2013-07-01
NAID 10031189209

Increased Norepinephrine by Medium-Chain Triglyceride Attributable to Lipolysis in White and Brown Adipose Tissue of C57BL/6J Mice

Bioscience, biotechnology, and biochemistry 76(6), 1213-1218, 2012-06-23
NAID 10030818451

Related Pictures

★リンクテーブル★

リンク元	「β3アドレナリン受容体」「adrenergic beta-3 receptor」
関連記事	「adrenergics」「adrenergic」「beta」「be」「adrenergic receptor」

「β3アドレナリン受容体」

Adrenoceptor beta 3
Available structures
PDB	Ortholog search: PDBe, RCSB
List of PDB id codes
	2CDW
Identifiers
Symbols	ADRB3 ; BETA3AR
External IDs	OMIM: 109691 MGI: 87939 HomoloGene: 37250 IUPHAR: 30 ChEMBL: 246 GeneCards: ADRB3 Gene
Gene ontology
Molecular function	• beta-adrenergic receptor activity; • protein binding; • beta3-adrenergic receptor activity; • beta-3 adrenergic receptor binding; • protein homodimerization activity; • epinephrine binding; • norepinephrine binding;
Cellular component	• nucleus; • plasma membrane; • integral component of plasma membrane; • receptor complex;
Biological process	• temperature homeostasis; • diet induced thermogenesis; • vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure; • desensitization of G-protein coupled receptor protein signaling pathway by arrestin; • carbohydrate metabolic process; • generation of precursor metabolites and energy; • energy reserve metabolic process; • receptor-mediated endocytosis; • G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; • adenylate cyclase-modulating G-protein coupled receptor signaling pathway; • activation of adenylate cyclase activity; • cell-cell signaling; • aging; • response to cold; • heat generation; • negative regulation of multicellular organism growth; • eating behavior; • positive regulation of MAPK cascade; • response to antibiotic; • brown fat cell differentiation; • adenylate cyclase-activating adrenergic receptor signaling pathway;
	Sources: Amigo / QuickGO
RNA expression pattern
	More reference expression data
Orthologs
	v; t; e;